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ABSTRACT
Elderly patients with type 2 diabetes mellitus
(T2DM) are a rapidly emerging population that
presents unique clinical challenges. This diverse
patient group can differ widely in terms of
physical and mental status, which can increase
their risk of complications including
hypoglycemia, falls, and depression. These
factors can negatively impact their glycemic
control, safety, and quality of life. The risk of
hypoglycemic events is elevated among elderly
patients with diabetes. In many cases, these
events are related to antidiabetic therapy and
the pursuit of strict glycemic control. Fear of a
hypoglycemic episode, on the part of the patient
and/or healthcare provider, is another major
barrier to achieving glycemic control.
Hypoglycemic events, even in the absence of
awareness of the event (asymptomatic), can have
negative consequences. To help manage these
risks, several national and international
organizations have proposed guidelines to
address individualized treatment goals for older
adults with diabetes. This article reviews current
treatment guidelines for setting glycemic targets
in elderly patients with T2DM, and discusses the
role of emerging treatment options in this
patient population.
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INTRODUCTION
Among persons aged 65 years and older living
in the United States, the estimated prevalence
of diabetes mellitus ranges from 22% to 33%
[1]. The number of older individuals with
diabetes is expected to grow as the US
population ages [1]. By 2050, projections
suggest that almost 26.7 million persons aged
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65 years and older living in the United States
will be diagnosed with diabetes [2, 3].
Type 2 diabetes mellitus (T2DM) accounts
for 90–95% of diabetes cases in adults [4].
As with younger adults, achieving and
maintaining glycemic control is important in
elderly patients with T2DM to prevent acute
complications of hyperglycemia and reduce the
risk of long-term complications [5, 6]. Although
some elderly patients will be able to maintain
glycemic control with lifestyle modification and
oral antidiabetic drugs (OADs), most will
eventually require insulin because of the
progression of T2DM [7–9].
Management of T2DM in elderly patients is
complicated by the clinical and functional
heterogeneity of this patient population [6].
Some older patients with T2DM may have
developed the disease in middle age and
experienced years of comorbidity, whereas
others may be newly diagnosed or may have
had years of undiagnosed comorbidity or few
complications. Older adults also differ with
regard to physical robustness, physical and
cognitive functioning, health status, and life
expectancy. Clinicians who treat elderly patients
with T2DM must consider this heterogeneity
when setting and prioritizing treatment goals.
Furthermore, older adults with diabetes are
more likely than older non-diabetic adults to
suffer from geriatric syndromes, including
conditions such as polypharmacy, depression,
cognitive impairment, urinary incontinence,
chronic pain, and injurious falls [1, 5, 6]. It is
also important to consider pharmacokinetics
when establishing a medication regimen for
elderly patients with T2DM [10]. In particular,
changes in renal function are common in the
elderly and may affect drug metabolism. These
and other considerations are listed in Table 1 [6,
11–16].
When managing T2DM in the elderly, it
is important to minimize the risk of
hypoglycemia. Older patients with diabetes are
at a greater risk than are younger patients, even
after adjusting for glycemic control [17]. In
addition, hypoglycemia presents a higher risk
for comorbid events and mortality in elderly
patients with diabetes compared with younger
patients [1]. Hypoglycemic events in the elderly
are independently associated with an increased
risk of fall-related fractures and acute
cardiovascular events. These events have been
shown to adversely impact health-related
quality of life as much as, or to an even
greater degree than, complications of T2DM
[18–20]. Furthermore, evidence suggests that
severe hypoglycemic episodes may increase the
risk of dementia in patients with T2DM [15].
Conversely, the presence of geriatric syndromes
may contribute to the increased risk of
hypoglycemia and its complications in elderly
patients with T2DM and should be assessed
when evaluating hypoglycemia risk (Table 2)
[1, 5, 17, 21–25].
The hypoglycemic risk associated with some
antidiabetic agents may present the greatest
barrier to optimal glycemic control in elderly
patients [26]. Therefore, diabetes therapies with
the lowest rates of hypoglycemia should be
considered for this patient population.
Emerging treatment options that may meet
this need include both approved and
investigational incretin-based therapies and
sodium glucose co-transporter 2 (SGLT2)
inhibitors, as well as ultra-long-acting insulins
that are in late-stage clinical development. The
aim of this article is to review current treatment
guidelines for setting glycemic targets in elderly
patients with T2DM, and to discuss the role of
emerging treatment options for this patient
population.
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Table 1 Characteristics to consider when individualizing therapy in older patients with type 2 diabetes mellitus (T2DM)
Clinical characteristics Considerations
Comorbid conditions [6, 12, 13] Younger age at T2DM onset increases cumulative exposure to hyperglycemia and
subsequent risk for complications; older age at onset is associated with higher
probability of existing comorbidities and shorter life expectancy
Greater disease burden may increase number of medications, potentially leading to
confusion, errors, poor adherence, increased adverse effects, costs, drug–drug
interactions, and patient frustration
Patients with other medical conditions expected to reduce life expectancy (i.e.,
shorten the period during which diabetic complications might develop) should be
assigned higher HbA1c targets
Frailty and ability to self-manage should be addressed and complexity of therapy
tailored accordingly
T2DM duration [12] Intensive treatment may be more likely to have beneﬁts the earlier it is begun. This
may especially be true in patients with a family history of early CAD
Presence of macrovascular (CV)
disease [11, 12, 14]
T2DM patients with a history of myocardial infarction are at high risk for recurrent
events
Intensive treatment in patients with a prior CV event may not reduce new events or
decrease mortality
Higher HbA1c targets may be more appropriate for older patients with a prior CV
event
Greater reductions in morbidity and mortality may result from control of CV risk
factors than from tight glycemic control in older patients with T2DM
History of severe hypoglycemia
[12, 15]
Dementia is associated with episodes of severe hypoglycemia
Less intensive HbA1c targets are appropriate for patients with recent severe
hypoglycemia
Psychological, social, and economic characteristics
Safety concerns and support
systems [12]
Highly intensive targets are inappropriate for insulin-treated patients who live alone
and have no routine daily check made by family, friends, or neighbors
Patient education and health coaching may have positive effects on patient
empowerment, self-care, and outcomes
Adverse effects of medications
[6, 12]
Insulin or sulfonylureas: possible weight gain, edema, heart failure
Thiazolidinediones: possible fractures
Metformin and certain incretin-based therapies: gastrointestinal adverse effects
Medication reactions increase with polypharmacy. Because intensive glycemic targets
require polypharmacy, the risk–beneﬁt ratio of adding other drugs should be
carefully balanced with the need to intensify therapy
Psychological and cognitive status
[6, 12, 15]
Depression limits successful goal attainment
Loss of cognitive function may be ampliﬁed in older T2DM patients with mild
clinical or subclinical cerebrovascular disease or concomitant Alzheimer’s disease
Economic considerations [12, 16] Cost of therapy may be prohibitive for patients on a ﬁxed income
Consider treatment with older, less expensive drugs that are still effective, especially if
less stringent targets are most appropriate
All-cause mortality rates for T2DM patients are higher among lower socioeconomic
groups
Quality of life [12] T2DM is associated with a 2- to 3-fold higher prevalence of functional disabilities
and comorbid conditions, mostly related to CV disease and obesity
CAD coronary artery disease, CV cardiovascular, HbA1c glycosylated hemoglobin






Over the past several years, various US and
international organizations have proposed
guidelines for establishing glycemic goals
(mainly glycosylated hemoglobin; HbA1c) in
patients with T2DM and have addressed the
need to individualize these goals in older adults
[1, 6, 27]. Although guidelines differ with
respect to their stringency and conceptual
frameworks, there is a general agreement that
the potential benefits of achieving tight
glycemic control for the individual should be
balanced with the risk of hypoglycemia,
given the patient’s clinical and functional
characteristics.
Current treatment guidelines from the
American Diabetes Association (ADA) consider
the avoidance of hypoglycemia to be of great
importance in setting glycemic goals,
particularly in older adults [5]. In addition, the
clinical and functional heterogeneity of older
adults with T2DM must be considered when
establishing and prioritizing treatment goals.
Older adults who have significant life
expectancy and are active with good cognitive
function may be treated using goals developed
for younger adults with diabetes (i.e.,
HbA1c\7%), but it is reasonable to set less
intensive glycemic goals (e.g., \8%) for elderly
patients with advanced diabetes complications,
life-limiting medical comorbidities, or
substantial cognitive or functional impairment
[5]. The latter group of patients is less likely to
benefit from a reduced risk of microvascular
Table 2 Geriatric syndromes and additional factors that contribute to hypoglycemia in the elderly [5, 17, 21–25]
Contributing factors Considerations
Poor cognitive function Increases risk of severe hypoglycemia in patients with T2DM
Severity of deﬁcits increases the risk
Greater rate of decline increases the risk
Impaired metabolic and
clearance processes
Higher risk (vs. younger patients) for hypoglycemia-associated compromised renal
function
Altered drug elimination compared with younger patients
Rate of insulin clearance from the circulation may decline with age
Hypoglycemia counter-regulation is impaired; less efﬁcient compensatory mechanisms to
avoid hypoglycemia
Polypharmacy Receiving C5 medication classes is associated with severe hypoglycemia
In addition to sulfonylureas, angiotensin-converting enzyme inhibitors and non-selective
beta-adrenoceptor antagonists can predispose to hypoglycemia
Comorbidity Heart failure and clinically relevant depression are predictors of hypoglycemia in elderly
patients with T2DM
Elderly patients with diabetes are at increased risk for geriatric syndromes such as polypharmacy, urinary incontinence,
depression, falls, chronic pain, and cognitive impairment
T2DM type 2 diabetes mellitus
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complications, and more likely to experience
serious hypoglycemia-related adverse events.
In 2012, a Consensus Development
Conference on Diabetes and Older Adults was
convened by the ADA to update diabetes
treatment guidelines for older adults and
address a variety of issues that may be unique to
treating diabetes and common comorbidities in
the elderly [1]. The framework for establishing
reasonable HbA1c targets utilizes a range based
on patient characteristics. Older adults who have
few coexisting chronic illnesses and a life
expectancy[10 years are recommended to have
an HbA1c target of\7.5%. For frail older adults,
patients whose life expectancy is \5 years, and
others in whom the risks of tight glycemic
control outweigh the benefits, a reasonable
HbA1c goal is\8.5%. These new guidelines, like
the existing ADA guidelines [5, 28], acknowledge
the clinical and functional heterogeneity of this
patient population and replace the more
stringent guidelines for improving the care of
older adults with diabetes released in 2003 by the
California Healthcare Foundation (CHF) and the
American Geriatrics Society (AGS) [6]. The
benefits and risks of implementing the earlier
CHF/AGS guidelines were examined in the
setting of a community-based, all-inclusive care
program for the elderly [29]. Implementation of
the guidelines in frail older patients with diabetes
ultimately resulted in dramatic improvements in
glycemic control based on HbA1c levels and
reductions in overall rates of hypoglycemic
episodes. However, the risk of a hypoglycemia-
related visit to the emergency department more
than doubled in the early phase of guideline
implementation. These findings emphasize the
importance of close monitoring for severe
hypoglycemia when aiming to achieve
glycemic goals in frail elderly patients.
Guidelines from the Department of Veterans
Affairs and the Department of Defense propose
an explicit risk-stratification approach based on
the patient’s physiologic age or the presence
and severity of microvascular complications
and major comorbidities [27]. These guidelines
suggest the following targets:
• an HbA1c level of \7% for patients with
life expectancy [10 years, no major
comorbidity and absent/mild microvascular
complications;
• an HbA1c\8% for those with life
expectancy 5–10 years and moderate
comorbidity if microvascular complications
are absent, mild, or moderate, or if life
expectancy is [10 years with moderate
microvascular complications;
• an HbA1c of 8–9% if life expectancy is
\5 years (major comorbidity) whether
microvascular complications are absent,
mild, moderate, or advanced [27].
A recent publication that considered the
results of clinical trials in older adults with
T2DM proposed a framework for
individualizing glycemic targets in the
outpatient setting [12]. The authors concluded
that establishing an individualized goal requires
consideration of both clinical characteristics and
the psychosocioeconomic setting. The most
intensive glycemic control can be targeted in
patients who are highly motivated, treatment-
adherent and knowledgeable with excellent self-
care capacities and comprehensive support
systems. In contrast, the least stringent level of
glycemic control (HbA1c * 8%) should be
targeted for patients who are less motivated and
non-adherent with limited insight, poor self-care
capacities, and weak support systems. Table 3
[12] shows the proposed approximate HbA1c
targets for older adults with T2DM as determined
by clinical characteristics, in the absence of
severe hypoglycemia.
The International Association of Gerontology
and Geriatrics, the European Diabetes Working
Diabetes Ther (2013) 4:239–256 243
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Party for Older People, and the International
Task Force of Experts in Diabetes published a
position statement in 2012 on the management
of diabetes in older adults, explicitly addressing
the need to avoid hypoglycemia [30]. In general,
an HbA1c target range of 7.0–7.5% should be set,
but a more precise goal based on clinical
characteristics may need to be recommended.
To reduce the risk of hypoglycemia, no patient
should have an on-treatment fasting blood
glucose (FBG) level of \6.0 mmol/L (108 mg/
dL), and blood glucose levels below 5 mmol/L
(90 mg/dL) should be strictly avoided.
Furthermore, glucose-lowering therapy should
not be initiated unless the FBG level is






The incretins glucagon-like peptide-1 (GLP-1)
and glucose-dependent insulinotropic
polypeptide (GIP) are peptide hormones that
are released into the small intestine following a
meal and stimulate insulin release from
pancreatic beta cells in a glucose-dependent
manner [31]. In addition, GLP-1 suppresses
glucagon release from alpha cells. These
actions result in an increase in glucose uptake
by tissues and a decrease in the release of
glucose from the liver. The incretin hormone
GLP-1 also delays gastric emptying. Both GLP-1
and GIP are rapidly metabolized by the enzyme
dipeptidyl peptidase-4 (DPP-4).
Currently approved incretin-based therapies
in the United States include GLP-1 receptor
agonists (exenatide and liraglutide) and DPP-4
inhibitors (sitagliptin, linagliptin, saxagliptin,
and alogliptin). The GLP-1 receptor agonist
lixisenatide is being reviewed by the US Food
and Drug Administration (FDA) for the
treatment of T2DM [32].
GLP-1 receptor agonists are administered
subcutaneously, whereas DPP-4 inhibitors are
administered orally [31]. Differences also exist
in the efficacy of GLP-1 receptor agonists and
DPP-4 inhibitors. A recent meta-analysis of
randomized controlled trials comparing
Table 3 Proposed approximate HbA1c targets for older patients with T2DM based on clinical characteristics (in the







[65–75 years Shorta None and none/early Less intensive (*7.0%)
Longb None and none/early Not intensive (7.0–8.0%)
Any Established and/or advanced Moderately intensive (*8.0%)c
[75 years or inﬁrm
at any age
Any Any Moderately intensive (*8.0%)c
Reproduced with permission from Ismail-Beigi et al. [12]
HbA1c glycosylated hemoglobin, T2DM type 2 diabetes mellitus
a Approximately 5–10 years or less
b Approximately 10–20 years or more
c Goal is to lessen the risk for hypoglycemia while reducing the risk of severe glycosuria, water and electrolyte loss,
infections, and nonketotic hyperosmolar coma
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treatments with placebo or other diabetes
medication showed that greater reductions in
HbA1c are obtained with GLP-1 receptor agonists
than with DPP-4 inhibitors (*1.0% vs.
0.6–0.8%) [33]. Similarly, a recent literature
analysis showed that treatment with GLP-1
receptor agonists results in significantly reduced
HbA1c levels and bodyweight compared with
DPP-4 inhibitors [34]. This is consistent with
greater patient satisfaction favoring GLP-1
receptor agonists over DPP-4 inhibitors [34].
Both therapies require dose titration during
initiation and are associated with a low risk of
hypoglycemia. Overall, incretin-based therapies
may be an important treatment option for
elderly patients with T2DM [35, 36].
Exenatide and liraglutide are approved by the
FDA for use as an adjunct to diet and exercise to
improve glycemic control in patients with T2DM
[37, 38]. However, neither exenatide nor
liraglutide are recommended as first-line
therapy for patients with inadequate glycemic
control on diet and exercise. An extended-release
formulation of exenatide (BydureonTM; Amylin
Pharmaceuticals, San Diego, CA), administered
by subcutaneous injection once weekly, also has
been approved for the management of T2DM
[39]. A post-hoc analysis of pooled data from 16
randomized controlled trials of 12–30 weeks’
duration, which included 2,067 patients with
T2DM treated with exenatide (10 lg twice daily),
demonstrated comparable improvements in
glycemic control in patients aged \65 years
(n = 1,613) and those aged C65 years (n = 454);
the mean change in HbA1c was -0.9% in
younger patients and -1.0% in older patients
(both, P\0.0001) [40]. Hypoglycemia was more
common among patients taking a concomitant
sulfonylurea (age \65 years, 27.7%; C65 years,
30.2%) than in those who were not receiving
such treatment (age\65 years, 4.0%; C65 years,
1.2%) [40].
A pooled analysis of six randomized trials
compared the effects of liraglutide (1.2 or
1.8 mg) with placebo in adults with T2DM
aged \65 years (n = 2,231) versus those aged
C65 years (n = 552) [41]. After 26 weeks of
treatment, reduction in HbA1c from baseline
was statistically significantly greater for both
doses of liraglutide than for placebo in both age
groups. For patients C65 years, liraglutide
changed HbA1c by -1.35% at 1.8 mg and
-1.32% at 1.2 mg dose compared to placebo
(-0.45%). For patients \65 years, liraglutide
changed HbA1c by -1.39% and -1.31% at
each dose, respectively, whereas patients on
placebo only changed by -0.21% (all, P\0.05).
Similarly, liraglutide reduced FPG from baseline
at both dosages for both age groups compared
to placebo (all, P\0.0001). The proportion of
patients reporting minor hypoglycemia,
characterized as an event in which the patient
had a plasma glucose level of \56 mg/dL and
did not require assistance to treat, was low
(4–15%) and generally comparable between
the two age groups for each dose. Of the six
patients who reported major hypoglycemia,
characterized as an event during which the
patient required assistance with food, glucagon
or intravenous glucose to treat, all had received
liraglutide 1.8 mg in addition to a sulfonylurea,
and all were aged \65 years [41].
The safety of exenatide and liraglutide has
been called into question, and both agents have
black box warnings (BBWs) as part of their
labeling. Exenatide has a BBW for medullary
thyroid cancer (MTC) and a Risk Evaluation and
Mitigation Strategy is ongoing to properly
evaluate the benefit of the drug compared
with the risk of MTC and acute pancreatitis.
The FDA have also requested an additional
study to assess the risk of other adverse events
(e.g., pancreatic cancer, renal disorders, and
serious hypoglycemia) [42]. Liraglutide also has
Diabetes Ther (2013) 4:239–256 245
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a BBW for risk of thyroid C-cell tumors,
including MTC, and is contraindicated in
patients with a history of MTC and in patients
with multiple endocrine neoplasia syndrome
type 2 [38].
The efficacy and safety of the experimental
GLP-1 agonist lixisenatide (20 mg/day) in 379
patients aged C65 years were evaluated in an
analysis of data from six randomized, placebo-
controlled, phase 3 trials [32]. In all studies,
comparable decreases in HbA1c levels were
observed in patients aged \65 years and older
patients, and significantly greater decreases in
HbA1c levels were obtained with lixisenatide
versus placebo in both age groups. The
incidence of symptomatic hypoglycemia
varied depending on background treatment
and usually was comparable between the
lixisenatide and placebo groups; no relevant
differences were observed between younger
patients and those aged C65 or C75 years [32].
The DPP-4 inhibitors sitagliptin, linagliptin,
saxagliptin, and alogliptin are FDA-approved as
an adjunct to diet and exercise, for use as
monotherapy or in combination therapy, in
adults with T2DM [43–46]. Data published in
presentation abstract form are available from a
study of linagliptin in elderly patients and
from analyses of data in elderly patients
participating in clinical trials of sitagliptin or
saxagliptin [47–50].
A 24-week, phase 3, randomized, placebo-
controlled trial evaluated linagliptin 5 mg/day
in 241 patients (aged C70 years) with T2DM
inadequately controlled despite metformin,
sulfonylurea, and/or insulin therapy [49].
From placebo, the mean change in HbA1c
level with linagliptin at 24 weeks was -0.64%
(P\0.0001). Although hypoglycemia was more
common in the linagliptin group than in the
placebo group (24.1% vs. 16.5%, respectively),
the difference was not statistically significant.
Hypoglycemic events occurred predominantly
in patients receiving concomitant insulin and/
or sulfonylurea therapy. These findings suggest
that adjunctive linagliptin is effective in elderly
patients with inadequately controlled T2DM
and does not impose an excess risk of
hypoglycemia. However, when linagliptin is
used in combination with insulin or a
sulfonylurea, it may be necessary to lower the
insulin or sulfonylurea dose to reduce the risk of
hypoglycemia.
A 24-week, randomized, double-blind,
placebo-controlled, parallel-group study
evaluated sitagliptin monotherapy in 206
elderly patients with T2DM [51]. Patients
received sitagliptin 50 or 100 mg (depending
on renal function) or placebo. The mean age of
patients was 72 years and mean baseline HbA1c
was 7.8%. The between-group difference
(sitagliptin - placebo) of least-squares mean
change in HbA1c level for patients with a
baseline HbA1c C 9.0% was -1.6% (P = 0.043).
Mean average blood glucose levels decreased
rapidly once the treatment commenced, with
significant improvements observed as early as
day 3 of treatment. No incidences of
hypoglycemia were reported, and the drug was
well tolerated in this population of older
patients [51].
A post-hoc analysis of pooled data from three
randomized, double-blind studies of 373 elderly
(aged C65 years) patients compared the effects
of sitagliptin versus glipizide or glimepiride
added to metformin or diet alone [47]. At
30 weeks, both HbA1c and FBG levels had
decreased in both the sitagliptin and
sulfonylurea treatment groups, with no
statistically significant differences between
treatment modalities. However, the incidence
of symptomatic hypoglycemia (i.e., that
reported as an adverse event) among elderly
patients was significantly lower in the
246 Diabetes Ther (2013) 4:239–256
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sitagliptin group than in the sulfonylurea group
(6.2% vs. 28.2%; P\0.001).
A once-daily formulation of a sitagliptin/
metformin combination (Janumet XRTM; Merck
& Co., Inc, Whitehouse Station, NJ, USA) was
approved by the FDA in 2012 for the
management of patients with T2DM [52]. This
combination has been shown to be bodyweight
neutral and has an acceptable risk of
hypoglycemia; its once-daily dosing may lower
the ‘pill burden’—an important factor especially
for elderly patients [53]. However, it has a BBW
for lactic acidosis in the labeling. Metformin-
containing medications should be used
cautiously in patients with hepatic disease and
those aged [80 years [53]. In addition, patients
taking sitagliptin alone or in combination
should be monitored for the development of
pancreatitis [53].
A sub-analysis compared the efficacy and
safety of saxagliptin in patients aged \65 years
(n = 351) with those aged C65 years (n = 104)
who had participated in a placebo-controlled
trial of adjunctive saxagliptin for T2DM
inadequately controlled with insulin alone or
insulin plus metformin [48]. At 24 weeks,
improvements in HbA1c, FBG, and
postprandial glucose levels were similar for
both age groups, with no statistically
significant interactions of treatment by age.
The incidence of hypoglycemia was not
reported, and no elderly patients discontinued
the study because of an adverse event [48].
In January 2013, the DPP-4 inhibitor
alogliptin received FDA approval for the
treatment of T2DM [46]. It is available in three
different formulations: as monotherapy
(NesinaTM; Takeda Pharmaceuticals America,
Inc, Deerfield, IL), as a fixed-dose combination
with metformin (KazanoTM; Takeda
Pharmaceuticals America, Inc, Deerfield, IL),
and as a fixed-dose combination with
pioglitazone (OseniTM; Takeda Pharmaceuticals
America, Inc, Deerfield, IL). Oseni carries a BBW
for heart failure due to the pioglitazone
component, and Kazano will have a BBW for
lactic acidosis due to the metformin component
[46].
The study of linagliptin and analyses of other
incretin-based therapies in older adults suggest
that elderly patients can benefit from these
agents at least as much as younger patients do,
without a substantial risk of hypoglycemia [47–
50, 54]. Phase 3 trials in elderly patients with
T2DM are ongoing or completed for sitagliptin
[55], saxagliptin [56], linagliptin [57], and
alogliptin [58]. The results of these studies will
provide additional insight on the risks and
benefits of incretin therapies in this patient
population. It should be noted that GLP-1
receptor agonists have been associated with an
increased risk of gastrointestinal adverse effects
(e.g., nausea and vomiting), while DPP-4
inhibitors pose an increased risk of
nasopharyngitis, urinary tract infection, and
headache [59]. GLP-1 receptor agonists also
are associated with mild weight loss, whereas
DPP-4 inhibitors are weight-neutral [59].
Requirements for dosage adjustment in
patients with renal impairment also differ
among the incretin-based therapies; however,
dose adjustment is not required for patients
who have mild hepatic impairment [37–39, 43–
45, 60–63]. Before incorporating incretin-based
therapies into an individualized regimen for the
elderly patient, differences in efficacy and
tolerability should be considered in relation to
the patient’s health status, comorbidities, and
concomitant medications.
SGLT2 Inhibitors
SGLT2 inhibitors comprise an emerging, novel
class of antihyperglycemic drugs that inhibit
Diabetes Ther (2013) 4:239–256 247
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glucose reabsorption in the kidney and increase
excretion of glucose in the urine [64, 65]. This
new, orally administered treatment strategy
directly lowers plasma glucose concentration
in an insulin-independent manner with a low
risk of hypoglycemia. A common adverse effect
of SGLT2 inhibitors is an increased incidence of
urinary tract and genital infections. Thus,
special caution is warranted in elderly patients
at higher risk of such infections, e.g., those with
urinary incontinence [66].
The SGLT2 inhibitor canagliflozin was
recently approved in the United States by the
FDA for the treatment of T2DM [67]. Another
SGLT2 inhibitor, dapagliflozin, has been
approved in the European Union but not in
the United States [67]. Additional SGLT2
inhibitors are currently under review by the
FDA.
A 102-week, randomized, double-blind,
placebo-controlled, phase 3 study evaluated
dapagliflozin (2.5, 5, or 10 mg) or placebo
added to metformin in 546 patients with
T2DM [68]. The mean change from baseline in
HbA1c level was ?0.02% for placebo compared
with -0.48% (P = 0.0008), -0.58% (P\0.0001),
and -0.78% (P\0.0001) for dapagliflozin 2.5, 5,
and 10 mg, respectively. All dapagliflozin groups
had sustained reductions in fasting plasma
glucose (FPG) and bodyweight. Recorded
hypoglycemic events were infrequent and not
severe in nature. An increase in reported urinary
tract infections and genital infections was
observed for all dapagliflozin groups compared
with placebo.
Clinical trials showed that canagliflozin also
improves glycemic control, reduces HbA1c, and
decreases bodyweight and systolic blood
pressure. A 52-week, randomized, double-
blind, phase 3 trial in adults with T2DM
compared the effects of canagliflozin 100 mg
(n = 483) or canagliflozin 300 mg (n = 485) with
glimepiride (n = 482) [69]. After 52 weeks of
treatment, reduction in Hb1Ac from baseline
changed -0.82% at 100 mg and -0.93% at
300 mg. The 300-mg canagliflozin dose was
statistically significantly superior versus
glimepiride (-0.12% [95% CI -0.22 to -0.02].
Canagliflozin was generally well tolerated;
however, both men and women who received
canagliflozin reported a greater number of
genital mycotic and urinary tract infections.
Genital mycotic infections were reported by 7%
of men and 11% of women taking canagliflozin
100 mg compared to 1% of men and 2% of
women taking glimepiride. At the 300 mg dose
of canagliflozin, 8% of men and 14% of women
reported this adverse event.
Notably, a 26-week, randomized, double-
blind, placebo-controlled, phase 3 clinical trial
investigated the use of canagliflozin in 716
adults aged 55–80 years with T2DM [70].
Results demonstrated that canagliflozin was
effective and well tolerated in older patients
receiving background therapy with other
antidiabetic agents. Treatment with
canagliflozin 100 and 300 mg reduced HbA1c
levels at 26 weeks compared with placebo
(-0.60%, -0.73%, and -0.03%, respectively;
P\0.001). Additionally, treatment with
canagliflozin at either dosage reduced
bodyweight, FPG, and systolic blood pressure
compared with placebo. However, both
canagliflozin doses were associated with
higher rates of urinary tract infections, genital
mycotic infections, and documented
hypoglycemia rates compared with placebo.
For patients taking canagliflozin 100 mg,
genital mycotic infections were reported by
3.2% of men and 15.4% of women compared
to 0% of men and 2.1% of women in the
placebo group. At the 300 mg dose of
canagliflozin, this adverse event was reported
by 6.2% of men and 11.2% of women.
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Basal Insulins
Of the currently approved antidiabetic
treatments, insulin is the most effective when
properly dosed, but there has been a general
trend toward under-utilization of insulin across
all age groups, including the elderly [71–73].
Recent findings suggest that patients aged
C70 years can achieve the same level of
glycemic control from insulin as do younger
patients [74].
In general, insulin analogs are preferred over
human insulin because they have a more
consistent pharmacokinetic profile and are
associated with lower rates of hypoglycemia
[75]. A recent pooled analysis of data from five
randomized controlled trials, involving a total
of 2,695 patients with inadequate control of
T2DM on OADs alone, suggests that the
addition of insulin glargine results in modestly
greater improvements in HbA1c (P\0.001) and
FBG (P\0.001) levels compared with NPH
insulin in patients aged C65 years, whereas in
younger patients (\65 years) similar glycemic
improvements were observed with the two
types of insulin [76]. Overall, among both
insulin groups (glargine and NPH), the rate of
nocturnal symptomatic hypoglycemia, but not
daytime (symptomatic or severe) or overall
severe hypoglycemia, was slightly but
significantly (P\0.05) higher for older adults
compared with younger adults [76]. Although
patients aged \65 years had significantly lower
rates of nocturnal symptomatic and severe
hypoglycemia with insulin glargine versus
NPH insulin, there were no between-treatment
differences in hypoglycemia rates among
patients C65 years of age [76].
A pooled analysis of three randomized, open-
label phase 3 trials of 22–26 weeks’ duration
(N = 1,296) compared insulin detemir with
NPH insulin in younger (\65 years) and older
(C65 years) adults with inadequately controlled
T2DM [77]. Patients received basal insulin once
or twice daily in combination with either bolus
insulin or an OAD, depending on the study.
Mean changes in HbA1c and FPG levels were
similar for the two treatment groups and for
both age groups. The relative risk of overall
hypoglycemia was significantly lower with
insulin detemir than with NPH insulin for
both age groups. However, the relative risk of
nocturnal hypoglycemia was statistically
significantly lower with insulin detemir in
patients aged \65 years, but not in those older
than 65 years [77].
Ultra-long-acting basal insulins in clinical
development may present an even lower risk of
hypoglycemia than currently available basal
insulin analogs, which would be especially
advantageous in elderly patients. Two such
insulins currently in development are insulin
degludec and LY2605541. Insulin degludec
incorporates structural modifications that allow
it to form soluble and stable multi-hexamers [78–
80]. Gradual separation of the monomers from
the multi-hexamers following subcutaneous
injection results in a protracted and continuous
delivery of insulin degludec into the circulation.
Insulin degludec demonstrates a flat and
stable glucose-lowering effect with once-daily
administration [78]. LY2605541, the other
investigational basal insulin analog, is a
derivative of insulin lispro that contains a
single polyethylene glycol (PEG) moiety [79,
81]. The large hydrodynamic size of the analog
enabled by the PEG moiety is believed to slow
both renal clearance and absorption from the
subcutaneous depot. LY2605541 exhibits low
intra-subject variability and has a longer serum
concentration–time profile and duration of
action than insulin glargine [81]. The smoother
pharmacokinetic and pharmacodynamic profiles
of these novel ultra-long-acting insulins may
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reduce the frequency and magnitude of blood
glucose troughs, thereby reducing the frequency
and severity of hypoglycemic episodes [79, 81].
Results of randomized, open-label, phase 3,
treat-to-target trials and of a meta-analysis of
patients with T2DM suggest that insulin
degludec achieves glycemic control that is
comparable to, or better than, that of insulin
glargine, with significantly lower rates of overall
confirmed and/or nocturnal confirmed
hypoglycemia [82–84]. A meta-analysis of
seven randomized, open-label, phase 3 trials of
insulin degludec in patients aged C65 years
with type 1 diabetes or T2DM found that rates
of nocturnal hypoglycemia, but not overall
confirmed hypoglycemia, were significantly
lower (by 35%) in patients treated with insulin
degludec versus insulin glargine [85]. Similarly,
a phase 2 study in patients with T2DM
demonstrated comparable glycemic control
with LY2605541 and insulin glargine, but
significantly lower rates of nocturnal
hypoglycemia (after adjusting for baseline
hypoglycemia) with LY2605541 [86]. Overall,
studies of insulin degludec and LY2605541 in
patients with T2DM suggest that these ultra-
long-acting formulations of insulin may allow
patients to achieve glycemic goals with a
reduced risk of hypoglycemia. Moreover, the
reduced risk of hypoglycemia may encourage
patients and physicians to target tighter
glycemic control. Both of these insulin
formulations were well tolerated and may
represent an important treatment option for
elderly patients with T2DM [82, 84].
CLINICAL CONSIDERATIONS
Attaining strict glycemic targets are associated
with an increased risk of hypoglycemic events
[87]. The occurrence of hypoglycemia is linked
with increased morbidity, mortality, and cost,
and minimizing hypoglycemia is thought to
increase adherence and satisfaction with
treatment strategies [88, 89]. Hypoglycemia
and fear of hypoglycemia in patients and
healthcare providers constitute a major
impediment to achieving appropriate glycemic
targets, especially in elderly patients.
Conversely, failure to recognize hypoglycemia
may lead to potentially catastrophic
consequences. Therefore, the prevention of
hypoglycemia is an important goal in
considering glycemic targets and treatment
strategies for individuals with T2DM. In
keeping with this, professional organizations
emphasize safety and avoidance of
hypoglycemia in their considerations for
choosing regimens and therapeutic agents.
Hypoglycemia remains a key barrier to
glycemic control in elderly patients with
T2DM. The presence of predisposing factors to
hypoglycemia, such as cognitive impairment
and renal impairment, must be considered
when setting glycemic goals and
individualizing therapy in the elderly [12, 15,
21]. In addition, numerous studies indicate a
direct correlation between hypoglycemia and
impaired cognitive function, which may
interfere with necessary self-care activities
required for managing blood glucose levels. A
recent study of 563 older adults demonstrated
that the executive function domain of
cognition was significantly associated with
HbA1c levels [90]. Improvement by one unit
in executive function directly correlated to a
0.23 decrease in HbA1c (P = 0.02). Tasci et al.
[91] conducted a prospective and observational
study in a small group of elderly individuals
with T2DM (n = 10) who began treatment with
vildagliptin 50 mg twice daily as an adjunct to
metformin. After a mean follow-up of
11 months, no significant changes in clinical
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cognitive function were found [91]. The impact
of diabetes treatment regimens on cognitive
performance in 3,421 elderly patients without
dementia was investigated [92]. As expected,
older adults with diabetes exhibited
significantly diminished performance in many
areas of cognitive functions compared with
non-diabetic patients, with diabetic patients
demonstrating a lower overall composite score
for the summary measure of cognitive
functioning (P = 0.01). However, there were
no significant differences in composite scores
between elderly patients with diabetes who
were being treated with insulin and/or
hypoglycemic medications and those who
were untreated [92].
Given the current state of knowledge,
avoidance of hypoglycemic events is an
important consideration in choosing a
therapeutic regimen in elderly individuals
with T2DM. Metformin constitutes the first
line of therapy, and its use is rarely associated
with hypoglycemic events [93, 94]. When
adequate glucose control necessitates
treatment therapies in combination with or as
an alternative to metformin, use of a DPP-4
inhibitor, GLP-1 receptor agonist, SGLT2
inhibitor, or insulin analog may be preferred
over sulfonylureas or traditional insulins if
hypoglycemia is a significant concern in
a particular patient. Thiazolidinediones
represent an additional class of antidiabetic
agents that increase insulin sensitivity and are
associated with a low risk of hypoglycemia [95].
Emerging therapies may offer effective and well-
tolerated treatment alternatives for elderly
patients with T2DM. Studies with incretin
therapies suggest that elderly patients may
achieve similar glycemic benefits to younger
patients with a low risk of hypoglycemia [35].
The long-term safety of DPP-4 inhibitors and
GLP-1 receptor agonists is under investigation.
The FDA requirement that evidence of
cardiovascular safety be provided for new
glucose-lowering agents means that all
medications developed to enhance incretin
action must be evaluated in long-term clinical
trials [96]. The forthcoming results of these
long-term studies should provide more
conclusive information about the safety of
GLP-1 receptor agonists, DPP-4 inhibitors, and
SGLT2 inhibitors in elderly patients with
diabetes.
CONCLUSION
The population of elderly patients with T2DM
in the United States is growing at an alarming
rate. Management of T2DM in elderly patients
is complicated, given their clinical and
functional diversity and the frequent presence
of geriatric syndromes, such as polypharmacy,
depression, and cognitive impairment.
Insulin remains the most effective treatment
for T2DM in elderly patients and can be titrated
to decrease any level of HbA1c to, or near, the
therapeutic goal. Although rates of severe
hypoglycemia are relatively low when basal
insulin analogs are used, reason for special
caution is required when these agents are used
concomitantly with sulfonylureas or in patients
at an increased risk of hypoglycemia. Ultra-
long-acting formulations of insulin in clinical
development, including insulin degludec and
LY2605541, appear to provide comparable or
improved glycemic control with a reduced risk
of hypoglycemia compared with insulin
glargine.
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